[Business Wire] – Celgene Corporation announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conf
Read more on this.
Celgene Corporation (CELG), valued at $73.90B, started trading this morning at $92.27.
Looking at the equity, the company’s one day range is $91.98 to $92.64 with the price of the stock fluctuating between $66.85 to $93.35 over the last 52 weeks.
Priced at 25.07x this year’s forecasted earnings, CELG shares are relatively expensive compared to the industry’s -4.96x forward p/e ratio.
According to a consensus of 21 analysts, the earnings estimate of $0.95 per share would be $0.17 better than the year-ago quarter and a $0.01 sequential increase. The full-year EPS estimate is $3.67, which would be a $0.69 better than last year.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $1.96 Billion. If realized, that would be a 17.37% increase over the year-ago quarter.
Recently, UBS upgraded CELG from Neutral to Buy (Dec 5, 2013). Previously, Argus upgraded CELG from Hold to Buy.
With the above information in mind, readers should note that the average price target is $100.03, which is 8.41% above where the stock opened this morning.
Summary (NASDAQ:CELG) : Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders; and strategic alliance with Forma Therapeutics. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Tag Helper ~ Stock Code: CELG | Common Company name: Celgene | Full Company name: Celgene Corporation (NASDAQ:CELG) .